GlassScriptPhysician profile
Yasser Rehman
NPI 1730372871
$422.53
in general payments reported to CMS, 2019-2025
13 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.18 · 2023: $81.83 · 2024: $190 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $124.74 | 2024 | |
| Merck Sharp & Dohme LLC | $41.04 | 2024-2025 | Keytruda, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $35.72 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $33.18 | 2021 | |
| Mirati Therapeutics, INC. | $24.69 | 2023 | Krazati |
| Janssen Biotech, INC. | $23.69 | 2023 | Imbruvica, Darzalex |
| Acrotech Biopharma INC. | $22.79 | 2024 | Beleodaq |
| Janssen Pharmaceuticals, INC | $22.76 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $22.69 | 2025 | |
| Urgo Medical North America, LLC | $22.61 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Amgen INC. | $19.88 | 2023 | Kyprolis |
| Genentech USA, INC. | $15.17 | 2025 | Columvi, Itovebi, Phesgo |
| Seagen INC. | $13.57 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.